Robert Barnabei, MD
Family Medicine · Charlotte, NCNPI 1396708285
Payments from drug & device makers
Across 192 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$579
- Novo Nordisk$505
- AbbVie$460
- Boehringer Ingelheim$263
- Lilly USA, LLC$143
- Bayer$117
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,11499%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $579 |
| Novo Nordisk | 39 | $505 |
| AbbVie(2 entities) | 32 | $460 |
| Boehringer Ingelheim | 17 | $263 |
| Lilly USA, LLC | 9 | $143 |
| Bayer | 7 | $117 |
| Sanofi-aventis U.S. LLC | 6 | $99 |
| Astellas Pharma US Inc | 5 | $93 |
| Novartis | 6 | $88 |
| Amarin Pharma, Inc. | 6 | $85 |
| Amgen | 6 | $79 |
| Eisai Inc. | 5 | $73 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $60 |
| Pfizer | 4 | $56 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $49 |
| GSK | 3 | $45 |
| Johnson & Johnson | 3 | $45 |
| Merck | 3 | $42 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Exeltis, USA Inc. | 2 | $27 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Medtronic | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Gilead | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,144 in reported general payments places this provider in the 80th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 810 | $226,609 |
| XareltoRivaroxaban | 132 | $44,436 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $39,727 |
| TrulicityDulaglutide | 44 | $38,011 |
| OzempicSemaglutide | 36 | $37,761 |
| MyrbetriqMirabegron | 232 | $36,883 |
| TivicayDolutegravir Sodium | 13 | $28,185 |
| DescovyEmtricitabine/Tenofov Alafenam | 14 | $28,127 |
| JardianceEmpagliflozin | 92 | $24,827 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 69 | $23,556 |
| LinzessLinaclotide | 43 | $21,871 |
| EntrestoSacubitril/Valsartan | 69 | $18,716 |
| Atorvastatin Calcium | 1,200 | $17,320 |
| Divalproex Sodium | 428 | $13,588 |
| MounjaroTirzepatide | 11 | $13,224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $56 | $250,165879 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $45 | $64,394129 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $143 | $51,23655 claims |
| Johnson & JohnsonXarelto | $45 | $44,436132 claims |
| Novo NordiskOzempic | $505 | $37,76136 claims |
| Astellas Pharma US IncMyrbetriq | $93 | $36,883232 claims |
| GileadDescovy | $13 | $28,12714 claims |
| Boehringer IngelheimJardiance | $263 | $24,82792 claims |
| AbbVieLinzess | $460 | $21,87143 claims |
| NovartisEntresto | $88 | $18,71669 claims |
| AstraZenecaFarxiga | $579 | $10,46543 claims |
| MerckJanuvia | $42 | $5,79919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Charlotte
- George RaadCharlotte$7.7M
- Steven BauerCharlotte$2.7M
- Melissa JonesCharlotte$1.8M
- Laura LuptonCharlotte$811K
- Kevin SodenCharlotte$558K
- Joseph KonenCharlotte$322K
- Thomas BarringerCharlotte$305K
- Richard RachimaCharlotte$294K
- Dimitrios HondrosCharlotte$275K
- Jewell CarrCharlotte$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.